Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Anderson, 1998, Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project, Ann Oncol, 9, 717, 10.1023/A:1008265532487 Horwitz, 2016, NCCN Guidelines insights: non-Hodgkin's lymphomas, version 3, J Natl Compr Canc Netw, 14, 1067, 10.6004/jnccn.2016.0117 d'Amore, 2015, Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 26, v108, 10.1093/annonc/mdv201 Savage, 2004, Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification, Ann Oncol, 15, 1467, 10.1093/annonc/mdh392 Simon, 2010, Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T-cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95, Br J Haematol, 151, 159, 10.1111/j.1365-2141.2010.08329.x Vose, 2008, International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes, J Clin Oncol, 26, 4124, 10.1200/JCO.2008.16.4558 Savage, 2008, ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project, Blood, 111, 5496, 10.1182/blood-2008-01-134270 Reimer, 2009, Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study, J Clin Oncol, 27, 106, 10.1200/JCO.2008.17.4870 d'Amore, 2012, Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01, J Clin Oncol, 30, 3093, 10.1200/JCO.2011.40.2719 Weisenburger, 2011, Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project, Blood, 117, 3402, 10.1182/blood-2010-09-310342 Jantunen, 2013, Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT, Blood, 121, 2529, 10.1182/blood-2012-11-466839 Perrone, 2014, Autologous stem cell transplantation for T-cell lymphomas, Semin Hematol, 51, 59, 10.1053/j.seminhematol.2013.11.002 Bossard, 2014, Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels, Blood, 124, 2983, 10.1182/blood-2014-07-584953 Sabattini, 2013, CD30 expression in peripheral T-cell lymphomas, Haematologica, 98, e81, 10.3324/haematol.2013.084913 Pro, 2016, Five-year survival data from a pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma, Blood, 128, 4144, 10.1182/blood.V128.22.4144.4144 Fanale, 2018, Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas, Blood, 131, 2120, 10.1182/blood-2017-12-821009 Swerdlow, 2008, vol 2 Cheson, 2007, Revised response criteria for malignant lymphoma, J Clin Oncol, 25, 579, 10.1200/JCO.2006.09.2403 Schemper, 1996, A note on quantifying follow-up in studies of failure time, Control Clin Trials, 17, 343, 10.1016/0197-2456(96)00075-X Ellin, 2014, Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry, Blood, 124, 1570, 10.1182/blood-2014-04-573089 Federico, 2018, Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T-cell Project Network, Br J Haematol, 181, 760, 10.1111/bjh.15258 Kluin-Nelemans, 2011, Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma, Ann Oncol, 22, 1595, 10.1093/annonc/mdq635 Advani, 2016, A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-cell consortium trial, Br J Haematol, 172, 535, 10.1111/bjh.13855 Foss, 2013, A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study, Leuk Lymphoma, 54, 1373, 10.3109/10428194.2012.742521 Dupuis, 2015, Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study, Lancet Haematol, 2, e160, 10.1016/S2352-3026(15)00023-X Mahadevan, 2013, Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350, Cancer, 119, 371, 10.1002/cncr.27733 Gleeson, 2018, CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial, Lancet Haematol, 5, e190, 10.1016/S2352-3026(18)30039-5 Schmitz, 2010, Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group, Blood, 116, 3418, 10.1182/blood-2010-02-270785 Horwitz, 2014, Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin, Blood, 123, 3095, 10.1182/blood-2013-12-542142 Pro, 2017, Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma, Blood, 130, 2709, 10.1182/blood-2017-05-780049 Carson, 2017, A prospective cohort study of patients with peripheral T-cell lymphoma in the United States, Cancer, 123, 1174, 10.1002/cncr.30416 D'Amore, 2009, Haematologica, 94, 437